PR Newswire All News ReleasesCodex · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 01:32:00·⟳ 抓取 01:32:16 +16s·⚡ 决策 08-23 01:33:26 +1m10s·66.0 天前
Rosen再次征集Disc Medicine投资者参与潜在证券集体诉讼调查
本条不是新的FDA决定、公司披露、正式诉讼进展或可量化赔付风险，而是律师事务所围绕已公开CRL事件的重复投资者征集；方向偏负面但增量不足，不能形成新的可执行做空或做多边际。
📄 原文PR Newswire All News Releases↗ 原文
NEW YORK, Aug. 22, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigat…
不做 Disc Medicine, Inc.（IRON.US）
不做Disc Medicine（IRON.US）：本次只是Rosen围绕2026-02-13已公开CRL的重复投资者征集稿，没有正式起诉、监管调查、赔付金额或公司新增审批失败；负面方向不足以满足强空催化，且无实时行情可支持ENTER。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Disc Medicine的实质负面事件是2026-02-13 FDA对bitopertin NDA发出CRL，公开资料显示当日公司已公告、SEC 8-K已披露且股价已大跌；Rosen在6月、7月已多次发布同类征集稿，本次2026-08-22稿件没有新增起诉、裁判、处罚、赔付或FDA进展，因此对IRON.US没有新的可交易预期差。
消息传播链
- Disc Medicine一手公告FDA对bitopertin治疗EPP的NDA发出CRL，并称FDA需要看到APOLLO三期结果。市场反应:公开报道显示IRON当日大幅下跌约21%-22%。
- 公司向SEC提交8-K披露CRL事项，并附公告及CRL文件。
- 公司披露Type A会议结果，称若APOLLO成功可作为CRL回复基础，预计2026年底前提交回复。
- Rosen已在7月发布同类投资者征集稿，内容与本次8月稿件高度重复。
- 本次信号为Rosen继续征集投资者参与潜在证券集体诉讼调查，未披露新增诉讼或监管事实。市场反应:事件发生在美股周末闭市，当前不可连续成交。
关键理由
- 本次稿件的基础事实是半年多前已公开的bitopertin CRL，而非新的监管失败或公司公告。
- 律师事务所投资者征集本身通常不改变公司现金流、药品审批路径或短期资产价值，除非出现正式诉讼进展或可量化赔付风险。
- 2026-06-09公司已披露Type A会议结果，FDA路径仍转向等待APOLLO三期数据和CRL回复，当前稿件未改变该路径。
主要风险
- 若后续出现正式集体诉讼立案、重大指控细节、监管调查或公司披露新增误导事实，应重新评估短线做空。
- 当前未能取得实时行情和内部案例库，不能用本次研究给出入场价或历史胜率校准。
反向证据
- 做空前查反向 · 来源 web · 日期 2026-06-09 · 影响 weakens
公司称与FDA对APOLLO若成功可支持CRL回复达成一致，预计年底前提交回复；这削弱把重复律师征集稿视为新增强空催化的理由。
检索:Disc Medicine bitopertin CRL Type A meeting APOLLO response 2026 原文 ↗ - 做空前查反向 · 来源 web · 日期 2026-07-10 · 影响 weakens
Rosen此前已多次发布相同投资者征集，说明本次不是首次传播的新法律风险。
检索:Rosen Disc Medicine securities class action investigation June July 2026 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足叠加无新增事实，强化不做而非开空；若未来出现正式起诉或监管调查，应以新事件重做研究。
方向:律师事务所重复征集稿本身通常只说明存量法律风险被营销扩散，方向偏负但缺少可交易强度。
涨幅量级:没有干净的同市场高相似先例和可用event_study结果，不能据此设定做空幅度。
形态:本条更接近旧负面事件后的重复法律广告，核心风险通常已在原始CRL日消化。
原文全文
展开原文 · 2,851 字
NEW YORK, Aug. 22, 2026 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing public.
So What: If you purchased Disc Medicine securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=56641 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
What is this about: On February 13, 2026, the U.S. Food and Drug Administration ("FDA") issued a Complete Response Letter ("CRL") to Disc Medicine regarding its bitopertin program. The FDA stated they could not approve Disc Medicine's new drug application ("NDA") as there were uncertainties in the NDA that would need additional evidence.
On this news, Disc Medicine's stock price fell 22% on February 13, 2026.
Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. The Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com
SOURCE THE ROSEN LAW FIRM, P. A.
Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing public.
So What: If you purchased Disc Medicine securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=56641 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
What is this about: On February 13, 2026, the U.S. Food and Drug Administration ("FDA") issued a Complete Response Letter ("CRL") to Disc Medicine regarding its bitopertin program. The FDA stated they could not approve Disc Medicine's new drug application ("NDA") as there were uncertainties in the NDA that would need additional evidence.
On this news, Disc Medicine's stock price fell 22% on February 13, 2026.
Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. The Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com
SOURCE THE ROSEN LAW FIRM, P. A.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。